Columvi Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed with a novel 2:1 structural format.
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed with a novel 2:1 structural format.
Researchers sought to determine whether epcoritamab would be effective in patients with LBCL.
Researchers sought to determine whether axi-cel would improve overall survival rates in patients with LBCL.
Researchers explored early lymphopheresis for CD19-based chimeric antigen receptor T-cell therapy for relapsed/refractory DLBCL.
Researchers sought to determine whether CAR-T therapy would be a viable option for patients with relapsed/refractory large B-cell lymphoma.
Researchers sought to determine physician preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma in the third line setting.
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
A study evaluating the use of chronotherapy for hematologic cancers identifies how the approach can improve outcomes for some patients.
Progression-free, overall survival significantly lower for female patients receiving chemo mostly in morning.